{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124558","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.605881+00:00","generated_at":"2026-05-30T02:05:27.357824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients","bullets":["Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.","Cash $271.1M, excluding $5M restricted cash; funding operations into Q4 2026.","ALLOHA Phase 1 heme trial: 16/16 treatment-arm patients relapse-free and MRD-negative as of July 8 cutoff; 3/11 control-arm relapses.","On track to dose first patient with multiplex TCR-T therapy and provide Phase 1 update by end of 2024.","IND filing for MAGE-A4-targeted TCR-T (TSC-202-A0201) planned by end of year."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124558","json":"https://secwatch.observer/filing/0000950170-24-124558.json","markdown":"https://secwatch.observer/filing/0000950170-24-124558.md","text":"https://secwatch.observer/filing/0000950170-24-124558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/0000950170-24-124558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/tcrx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:05:27.357824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}